Skip to content

Use of intravenous Methotrexate plus Glucocorticoid for the Treatment of Pemphigus:A multicenter,randomized and controlled clinical trial

Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12003540
Enrollment
Unknown
Registered
2012-12-19
Start date
2011-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus

Interventions

Sponsors

Institute of dermatology, Chinese Academyof Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) 18 to 75 years old, male or female; (2) Meet the diagnostic criteria for pemphigus(erythema and vesicles on skins and/or mucous membranes; dermatopathology shows bulla above the basal cell layer; direct or indirect immunofluorescence (DIF/IIF) staining reveals IgG and/or C3 deposited as reticular-pattern in the intercellular substance of the epidermis); (3) Skin lesion scores of Pemphigus Disease Area Index(PDAI) are between 30 to 90 points(scoring criteria refers to Appendix 11); (4) Patients completely understand the trial and voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Regimen or dose of treatment for pemphigus have changed within one month; (2) Esophagus involved; (3) Subjects who have severe local or systemic acute or chronic infection which is difficult to control and may affect the efficacy of the drugs or the clinical evaluation; (4) Subjects who have severe heart, lung, liver (ALT=1.5×ULN), kidney or other severe diseases; (5) Pregnant and lactating female or subjects who have fertility plan recently; (6) With a history of malignant tumor; (7) Subjects who are allergic to the test drugs or have contraindications; (8) With other skin diseases that may affect the clinical evaluation; (9) Other conditions which researchers consider the subjects not compatible to the trial.

Design outcomes

Primary

MeasureTime frame
PDAI;Date of stopping blisterring;Date of erosion surface completely drying;Date of glucocorticoid starting to reduce;Glucocorticoid dosage;

Secondary

MeasureTime frame
Electrocardiogram;CTChest X-ray/C;

Countries

China

Contacts

Public ContactBaoxi Wang

Institute of dermatology, Chinese Academyof Medical Sciences

wangbx@ncstdlc.org+86 025-85478071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026